Acrobiosystems for English
icon_bulk_orderAchat groupé/Commande rapide
user
  1. Tableau de bord
  2. Mon profil
  3. Mon adresse
  4. Mes commandes
  5. Adhésion à Acro
Connexion Inscription
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP IL-2 Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
Il n'y a pas de produit dans le panier !
Mon panier|Check Out
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Accueil > Latent TGF-beta 2

Latent TGF-beta 2

Brief Information

Name:Transforming growth factor beta 2
Target Synonym:TGF-beta-2,BSC-1 Cell Growth Inhibitor,Polyergin,Glioblastoma-Derived T-Cell Suppressor Factor,Cetermin,LDS4,TGFB2,Transforming Growth Factor, Beta 2,Transforming Growth Factor Beta-2 Proprotein,TGF-Beta2,Transforming Growth Factor Beta 2,G-TSF,Transforming Growth Factor beta2,LAP,Prepro-Transforming Growth Factor Beta-2
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Product> Filter Results
Par statut du produit :
Par catégorie de produit :
Par espèce :
Par étiquette :
Par conjugaison :
Cat . Non Espèces Description du produit Structure Pureté Caractéristique
TG2-H5243 Human Human Latent TGF-beta 2 / TGFB2 Protein, His Tag
TG2-H5243-structure
TG2-H5243-sds
ACRO Quality

Part of Bioactivity data

TG2-H5243-ELISA
Latent TGF-beta 2 ELISA

Immobilized Human Latent TGFB2, His Tag (Cat. No. TG2-H5243) at 5 μg/mL (100 μL/well) can bind Human LRRC32, Fc Tag (Cat. No. LR2-H5256) with a linear range of 0.039-0.625 μg/mL (QC tested).

Protocol

Synonym Name

Latent TGFB2,MGC116892,TGFβ2,TGF-beta2

Background

Transforming growth factor beta 2 ( TGFB2) is also known as TGF-β2, G-TSF, TGFB. is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The TGFB2 protein helps control the growth and division (proliferation) of cells, the process by which cells mature to carry out specific functions (differentiation), cell movement (motility), and the self-destruction of cells (apoptosis). The TGFB2 protein can inhibit the T cell growth by IL-2-dependent. and can inhibit immune surveillance during tumor development, the protein promoting tumor growth with an autocrine manner. TGF-β2 can affect the viability of killer cells and reduce the expression of IL-2, IL-6, IL-10, IFN-γ and other cytokines.TGFB2 plays an important role in controlling the immune system, and shows different activities on different types of cell, or cells at different developmental stages.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Trabedersen OT-101; AP-2/09; AP-2/09-DS; AP-12009; OT-201 Phase 3 Clinical Glioblastoma; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Mesothelioma; Astrocytoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms Details
Nisevokitug NIS-793 Phase 3 Clinical Xoma Corp Kidney Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma Details
ENERGI-F701 ENERGI-F701 Phase 2 Clinical Energenesis Biomedical Co Ltd Alopecia Details
TU-2218 TU-2218 Phase 2 Clinical TiumBio Co Ltd Solid tumours Details
LP-008 LP-008 Phase 1 Clinical Solid tumours Details
Trabedersen OT-101; AP-2/09; AP-2/09-DS; AP-12009; OT-201 Phase 3 Clinical Glioblastoma; Pancreatic Neoplasms; Coronavirus Disease 2019 (COVID-19); Mesothelioma; Astrocytoma; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Lung Neoplasms; Sarcoma; Cholangiocarcinoma; Breast Neoplasms; Microsatellite Instability; Vulvar Neoplasms; Nasopharyngeal Carcinoma; Prostatic Neoplasms; Colorectal Neoplasms; Oropharyngeal Neoplasms; Thymus Neoplasms; Gallbladder Neoplasms; Adenomyoepithelioma; Lymphoma; Brain metastases; Urogenital Neoplasms; Thymoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Sarcoma, Kaposi; Triple Negative Breast Neoplasms; Solid tumours; Hematologic Neoplasms; Head and Neck Neoplasms; Intestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Anus Neoplasms; Stomach Neoplasms; Carcinoma; Carcinoma, Renal Cell; Esthesioneuroblastoma, Olfactory; Biliary Tract Neoplasms; Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Carcinoma, Transitional Cell; Nose Neoplasms; Ganglioglioma; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms Details
Nisevokitug NIS-793 Phase 3 Clinical Xoma Corp Kidney Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Small Cell Lung Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Adenocarcinoma Details
ENERGI-F701 ENERGI-F701 Phase 2 Clinical Energenesis Biomedical Co Ltd Alopecia Details
TU-2218 TU-2218 Phase 2 Clinical TiumBio Co Ltd Solid tumours Details
LP-008 LP-008 Phase 1 Clinical Solid tumours Details

This web search service is supported by Google Inc.

totop
Call us
Call us

Germany+49 800 0826645

United Kingdom+44 808 281 3436

Netherlands+31 800 0224992

Switzerland+41 800 040 012

France+33 800 90 78 85

Sweden+46 20 12 76 94

Denmark+45 80 83 07 62

Belgium+32 800 27 125

Email
E-Mail
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland
linkedin twitter facebook youtube

Laisser un message

Copyright © 2017 ACROBiosystems. All Rights Reserved
Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap